PROMETHEUS BIOSCIENCES INC (RXDX) Stock Price, Quote, News and Overview
NASDAQ:RXDX - Nasdaq - US74349U1088 - Common Stock - Currency: USD
RXDX Quote, Performance and Key Statistics
199.92
+0.18 (+0.09%)
The current stock price of RXDX is 199.92 USD. In the past month the price increased by 3.62%. In the past year, price increased by 684.31%.
RXDX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RXDX
Company Profile
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
Company Info
PROMETHEUS BIOSCIENCES INC
3050 Science Park Road, #342
San Diego CALIFORNIA 92121 US
CEO: Mark C. McKenna
Employees: 97
Company Website: https://www.prometheusbiosciences.com/
Phone: 18584224300.0
PROMETHEUS BIOSCIENCES INC / RXDX FAQ
What is the stock price of PROMETHEUS BIOSCIENCES INC today?
The current stock price of RXDX is 199.92 USD. The price increased by 0.09% in the last trading session.
What is the ticker symbol for PROMETHEUS BIOSCIENCES INC stock?
The exchange symbol of PROMETHEUS BIOSCIENCES INC is RXDX and it is listed on the Nasdaq exchange.
On which exchange is RXDX stock listed?
RXDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROMETHEUS BIOSCIENCES INC stock?
15 analysts have analysed RXDX and the average price target is 198.9 USD. This implies a price decrease of -0.51% is expected in the next year compared to the current price of 199.92. Check the PROMETHEUS BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROMETHEUS BIOSCIENCES INC worth?
PROMETHEUS BIOSCIENCES INC (RXDX) has a market capitalization of 9.56B USD. This makes RXDX a Mid Cap stock.
How many employees does PROMETHEUS BIOSCIENCES INC have?
PROMETHEUS BIOSCIENCES INC (RXDX) currently has 97 employees.
What are the support and resistance levels for PROMETHEUS BIOSCIENCES INC (RXDX) stock?
PROMETHEUS BIOSCIENCES INC (RXDX) has a support level at 193.95 and a resistance level at 199.93. Check the full technical report for a detailed analysis of RXDX support and resistance levels.
Is PROMETHEUS BIOSCIENCES INC (RXDX) expected to grow?
The Revenue of PROMETHEUS BIOSCIENCES INC (RXDX) is expected to decline by -69.44% in the next year. Check the estimates tab for more information on the RXDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROMETHEUS BIOSCIENCES INC (RXDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RXDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RXDX, evaluating the profitability, health, valuation and growth aspects
- PROMETHEUS BIOSCIENCES INC (RXDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROMETHEUS BIOSCIENCES INC (RXDX) Sales and EPS estimates to see what analysts future expectations are.
- PROMETHEUS BIOSCIENCES INC (RXDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROMETHEUS BIOSCIENCES INC (RXDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROMETHEUS BIOSCIENCES INC (RXDX) Stock Chart to make your own analysis
- PROMETHEUS BIOSCIENCES INC (RXDX) Latest news and press-releases to stay up to date.
Does PROMETHEUS BIOSCIENCES INC (RXDX) stock pay dividends?
RXDX does not pay a dividend.
What is the Price/Earnings (PE) ratio of PROMETHEUS BIOSCIENCES INC (RXDX)?
PROMETHEUS BIOSCIENCES INC (RXDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).
RXDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RXDX. When comparing the yearly performance of all stocks, RXDX is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
RXDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RXDX. No worries on liquidiy or solvency for RXDX as it has an excellent financial health rating, but there are worries on the profitability.
RXDX Financial Highlights
Over the last trailing twelve months RXDX reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -26.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RXDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 72% to RXDX. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -16.9% and a revenue growth -69.44% for RXDX